# Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

> **NCT06839144** · PHASE2 · RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Ovarian Cancer
- Ovarian Cancer Metastatic Recurrent

## Interventions

- **DRUG:** Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)
- **DRUG:** Placebo (Matching for Propranolol & Etodolac)

## Key facts

- **NCT ID:** NCT06839144
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06839144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06839144, "Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06839144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*